🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Locally Advanced or Metastatic ER+ HER2- Breast Cancer

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites📍 Huntsville📍 Tucson📍 Duarte Genentech, Inc. · Tests: GDC-4198, Giredestrant, Abemaciclib A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site📍 Shanghai Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites📍 Anchorage📍 Chandler📍 Gilbert Pfizer · Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer NCT06954961Phase 32 sites📍 Beijing📍 Harbin InventisBio Co., Ltd · Tests: D-0502, Fulvestrant A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812Phase 1, Phase 222 sites📍 Hefei📍 Guangzhou📍 Huizhou Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766Phase 211 sites📍 Dijon📍 Limoges📍 Lyon Gustave Roussy, Cancer Campus, Grand Paris · Tests: U3-1402 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors NCT07540572Phase 111 sites📍 Plantation📍 East Brunswick📍 Lake Success IDEAYA Biosciences · Tests: IDE574, Fulvestrant injection Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation NCT05696626Phase 3224 sites📍 Scottsdale📍 Tucson📍 Santa Rosa LeonaBio · Tests: Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer NCT05573126Phase 1, Phase 214 sites📍 New Haven📍 Tampa📍 Boston Ellipses Pharma · Tests: EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868Phase 2, Phase 3295 sites📍 Hot Springs📍 Cerritos📍 Cerritos Bristol-Myers Squibb · Tests: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin Study of PF-07248144 in Advanced or Metastatic Solid Tumors NCT04606446Phase 243 sites📍 Scottsdale📍 Los Angeles📍 San Francisco Pfizer · Tests: PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy